Experimental chemotherapy with 5-arylpyrimidine antifolates: preliminary studies on toxicity and responsiveness of sarcoma 180 to DDMP (NSC-19494) and DDMP with citrovorum factor (NSC-3590).

Abstract

The 5-arylpyrimidine antifolate DDMP showed appreciable therapeutic activity against an ascitic form of Sarcoma 180 in BD2F1 mice. Antitumor effects were highly schedule and dose dependent at a limited number of doses within the range of 8--40 mg/kg. The best results (increased lifespan = 112%) were obtained with two doses of DDMP at 40 mg/kg given 4 days apart. The incorporation of citrovorum factor rescue in dose schedules with DDMP appeared to improve the therapeutic index. In multiple-dose schedules with citrovorum factor allowing an average of eight doses of DDMP at a maximum level of 16 mg/kg, increases in median lifespan were greater than 158% with a number of long-term survivors.

• Authors: F M Sirotnak, D M Dorick, D M Moccio
• Journal: Cancer treatment reports (Cancer Treat Rep) Vol. 60 Issue 5 Pg. 547-53 (May 1976) ISSN: 0361-5960 [Print] United States
• PMID: 1086715 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antineoplastic Agents
• Pyrimidines
• Leucovorin

Topics

• Animals
• Antineoplastic Agents (adverse effects, therapeutic use)
• Drug Therapy, Combination
• Female
• Leucovorin (therapeutic use)
• Mice
• Pyrimidines (adverse effects, therapeutic use)
• Sarcoma 180 (drug therapy)